Edwards Lifesciences Stock Price, News & Analysis (NYSE:EW)

18 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Edwards Lifesciences in the last year. There are currently 2 sell ratings, 8 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" EW shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EW, but not buy additional shares or sell existing shares.
View EW analyst ratings or view top-rated stocks.

18 brokers have issued 12-month price targets for Edwards Lifesciences' stock. Their EW share price targets range from $57.00 to $107.00. On average, they predict the company's stock price to reach $82.78 in the next twelve months. This suggests a possible upside of 22.8% from the stock's current price.
View analysts price targets for EW or view top-rated stocks among Wall Street analysts.

Edwards Lifesciences' stock was trading at $74.61 at the beginning of 2023. Since then, EW shares have decreased by 9.6% and is now trading at $67.43.
View the best growth stocks for 2023 here.

Edwards Lifesciences saw a decline in short interest during the month of November. As of November 15th, there was short interest totaling 10,750,000 shares, a decline of 6.3% from the October 31st total of 11,470,000 shares. Based on an average daily volume of 4,100,000 shares, the short-interest ratio is presently 2.6 days. Currently, 1.8% of the company's stock are short sold.
View Edwards Lifesciences' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, January 30th 2024.
View our EW earnings forecast.

Edwards Lifesciences Co. (NYSE:EW) issued its earnings results on Wednesday, October, 25th. The medical research company reported $0.59 EPS for the quarter, hitting analysts' consensus estimates of $0.59. The medical research company earned $1.48 billion during the quarter, compared to analyst estimates of $1.48 billion. Edwards Lifesciences had a net margin of 24.59% and a trailing twelve-month return on equity of 24.54%. Edwards Lifesciences's revenue was up 12.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.61 EPS.
Read the conference call transcript.

ETFs with the largest weight of Edwards Lifesciences (NYSE:EW) stock in their portfolio include iShares U.S. Medical Devices ETF (IHI), Neuberger Berman Disrupters ETF (NBDS), Global X Aging Population ETF (AGNG), First Trust Indxx Medical Devices ETF (MDEV), ETC 6 Meridian Quality Growth ETF (SXQG), BNY Mellon Sustainable US Equity ETF (BKUS), Goldman Sachs Future Health Care Equity ETF (GDOC) and Inspire 100 ETF (BIBL).

Edwards Lifesciences's stock split before market open on Friday, May 29th 2020. The 3-1 split was announced on Thursday, May 7th 2020. The newly created shares were issued to shareholders after the closing bell on Monday, May 18th 2020. An investor that had 100 shares of stock prior to the split would have 300 shares after the split.

Edwards Lifesciences updated its FY23 earnings guidance on Wednesday, October, 25th. The company provided earnings per share (EPS) guidance of $2.50-2.60 for the period, compared to the consensus EPS estimate of $2.55.

389 employees have rated Edwards Lifesciences Chief Executive Officer Michael A. Mussallem on Glassdoor.com. Michael A. Mussallem has an approval rating of 90% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Edwards Lifesciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), Home Depot (HD), Salesforce (CRM), Walt Disney (DIS), Visa (V), Johnson & Johnson (JNJ), QUALCOMM (QCOM), Micron Technology (MU) and CVS Health (CVS).

Edwards Lifesciences' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Bank of New York Mellon Corp (2.90%), Brown Advisory Inc. (2.49%), Morgan Stanley (1.17%), Northern Trust Corp (1.05%), Legal & General Group Plc (0.75%) and Sands Capital Management LLC (0.75%). Insiders that own company stock include Bernard J Zovighian, Catherine M Szyman, Catherine M Szyman, Daveen Chopra, Donald E Bobo Jr, Heisz Leslie Stone, Huimin Wang, Jean-Luc M Lemercier, Kieran Gallahue, Larry L Wood, Martha H Marsh, Michael A Mussallem, Michael A Mussallem, Nicholas J Valeriani, Robert WA Sellers and Scott B Ullem.
View institutional ownership trends.

Shares of EW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.